Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates

分组1 - Oncobiologics, Inc. reported a quarterly loss of $0.22 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.17, representing an earnings surprise of -26.95% [1] - The company posted revenues of -$1.21 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 131.38%, compared to zero revenues a year ago [2] - Oncobiologics shares have declined approximately 69% since the beginning of the year, contrasting with the S&P 500's decline of only 0.1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of $4.97 million, and for the current fiscal year, it is -$0.65 on revenues of $21.13 million [7] - The Medical - Biomedical and Genetics industry, to which Oncobiologics belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]